Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bexmarilimab + doxorubicin
- Development stage
- Unknown
- Lead developer
- Faron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bexmarilimab + doxorubicin is an investigational combination therapy being developed by Faron Pharmaceuticals, primarily for the treatment of soft tissue sarcomas. Bexmarilimab (FP-1305) is a humanized IgG4 monoclonal antibody that targets Clever-1 (Common Lymphatic and Endothelial Vessel Receptor-1), a scavenger receptor expressed on immunosuppressive M2 macrophages. By blocking Clever-1, bexmarilimab facilitates the conversion of these pro-tumoral macrophages into a pro-inflammatory M1 phenotype, thereby activating the immune system against the tumor. Doxorubicin is a well-established cytotoxic chemotherapy that works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. This combination, evaluated in the Phase 1 BEXAR trial, aims to synergize the direct cytotoxic effects of chemotherapy with immune-modulating macrophage reprogramming to improve outcomes in patients with advanced solid tumors.
- Other names
- bexmarilimab plus doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)STAB1 (Common lymphatic endothelial and vascular endothelial receptor 1)DNA
Beyond the preview
Go deeper on bexmarilimab + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bexmarilimab + doxorubicin.